BIO Critiques CMS' Justification Of ASP+4% For Hospital Outpatient Drugs
Executive Summary
The Biotechnology Industry Organization is maintaining its stance that if Medicare pays anything less than average sales price plus 6 percent for drugs and biologics in the hospital outpatient setting, hospital pharmacies will be under-reimbursed
You may also be interested in...
Medicare Holds Hospital Outpatient Payment For Drugs At ASP+4% For 2010
Draft rule for Part B hospital outpatient prospective payment system in 2010 goes against advisory panel recommendation to increase reimbursement to average sales price plus 6 percent. Other changes affecting drugs and biologicals are proposed.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials